Oncology Biosimilars Market is expected to Hit US$ 30.83 Billion by 2033 | Major Companies - Amgen Inc., Pfizer Inc., Biocon Biologics Limited, Sandoz Inc.

DataM Intelligence has unveiled its latest report on the "Oncology Biosimilars Market Size 2026" delivering powerful insights into key trends, future growth opportunities, and evolving market challenges. Designed to empower smarter decision-making, the report equips businesses with the strategic intelligence needed to stay ahead in a competitive landscape. By blending robust qualitative analysis with data-driven quantitative research, DataM Intelligence offers a well-rounded perspective that helps organizations decode complex market dynamics, unlock new avenues for growth, and seize emerging opportunities in an ever-evolving global market.

Unlock Strategic Partnerships in the Growing Oncology Biosimilars Market-Connect with Key Industry Leaders Today: https://www.datamintelligence.com/partner-identification-enquiry/oncology-biosimilars-market?sz

The Global Oncology Biosimilars Market size reached US$ 6.76 Billion in 2024 from US$ 5.77 Billion in 2023 and is expected to reach US$ 30.83 Billion by 2033, growing at a CAGR of 18.6% during the forecast period 2025-2033.

The Oncology Biosimilars Market refers to the global industry focused on the development, production, and commercialization of biosimilar versions of biologic drugs used in cancer treatment. These medicines are highly similar to approved reference biologics in safety, efficacy, and quality, offering cost-effective alternatives to expensive originator therapies. The market includes monoclonal antibodies, supportive care biologics, and targeted therapies used across various cancer types. It is driven by patent expirations, rising cancer prevalence, healthcare cost pressures, and increasing regulatory approvals worldwide globally.

Download Free Sample Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/oncology-biosimilars-market?sz

Recent Industry Developments: United States

✅ March 2026: FDA accelerates biosimilar approval pathway
The U.S. FDA issued draft guidance to streamline biosimilar clinical requirements, reducing or eliminating certain comparative studies when sufficient scientific justification exists. This is expected to cut development costs by up to 50%, accelerating oncology biosimilar launches and improving affordability for cancer therapies.

✅ February 2026: Expansion of oncology biosimilar access through pricing reforms
U.S. biosimilar stakeholders reported continued price erosion of oncology biologics (up to 70% in mature classes), driven by broader adoption of biosimilar trastuzumab, bevacizumab, and rituximab alternatives. Pharmacy Benefit Manager (PBM) restructuring is also improving reimbursement access for oncology patients.

✅ January 2026: Market maturation reaches 90+ approved biosimilars
By early 2026, the U.S. biosimilar ecosystem surpassed 90 total FDA approvals, with oncology representing a major share of approved and commercialized molecules. The market is shifting from early adoption to high penetration and competitive substitution across oncology biologics.

Recent Industry Developments: Japan

✅ March 2026: Regulatory push for faster biosimilar adoption
Japan's regulatory environment continued to support faster introduction of Western-approved oncology biologics as biosimilars, aiming to reduce "drug lag." Oncology remains a priority therapeutic area, especially for HER2, lymphoma, and colorectal cancer biologics.

✅ February 2026: Expansion of biosimilar oncology portfolio via licensing
Japanese pharma companies increased licensing agreements with global biotech firms to introduce oncology biosimilars domestically. This strategy is focused on improving access to high-cost cancer biologics and strengthening domestic oncology pipelines.

✅ January 2026: Rising oncology biosimilar utilization in hospital systems
Hospitals and insurers in Japan increased adoption of oncology biosimilars, particularly for trastuzumab and rituximab biosimilar equivalents, driven by cost-containment policies and government pressure to reduce oncology treatment expenditure.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/oncology-biosimilars-market?sz

List of the Key Players in the Oncology Biosimilars Market:

Celltrion USA, Inc.
Amgen Inc.
Pfizer Inc.
Biocon Biologics Limited
Teva Pharmaceuticals USA, Inc.
Organon group of companies
Accord BioPharma
Sandoz Inc.

How Does Market Research Work in the Oncology Biosimilars Market?

Market research for the Oncology Biosimilars Market involves systematic data collection and analysis to understand industry trends, customer behavior, and competitive dynamics. It includes primary research such as surveys and interviews, and secondary research from reports, databases, and publications. Analysts evaluate market size, growth drivers, challenges, and opportunities using qualitative and quantitative methods. Insights are validated through expert opinions and forecasting models, enabling businesses to make strategic decisions, identify target segments, and gain a competitive advantage in a rapidly evolving market.

Latest Mergers and Acquisitions of Oncology Biosimilars Market:

✅ April 2026: Sun Pharma Acquisition of Organon
➠ Sun Pharmaceutical Industries acquired Organon in a landmark $11.75 billion deal, expanding its footprint in biosimilars, oncology-related generics, and women's health portfolios. The acquisition gives Sun Pharma access to more than 70 established therapies and strengthens its global biologics and biosimilars pipeline, including oncology-adjacent assets.

✅ April 2026: Eli Lilly Acquisition of Kelonia Therapeutics
➠ Eli Lilly acquired Kelonia Therapeutics for approximately $7 billion, gaining access to its in-vivo cell therapy platform, which includes oncology-focused applications. This strengthens Lilly's position in next-generation cancer therapies, particularly in advanced biologics and engineered immune-cell approaches.

✅ April 2026: Gilead Sciences Acquisition of Tubulis
➠ Gilead Sciences acquired Tubulis in a deal worth $3.15 billion upfront (plus milestones) to enhance its oncology antibody-drug conjugate (ADC) capabilities. ADCs are a key growth area closely aligned with oncology biologics and biosimilar innovation trends.

Segments Covered in the Oncology Biosimilars Market 2026:

By Product Type: Monoclonal Antibodies (mAbs), Recombinant Proteins, Granulocyte Colony-Stimulating Factor (G-CSF), Erythropoiesis-Stimulating Agents, Others.

By Indication: Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Blood Cancer, Others.

By Route of Administration: Oral, Injectable.

Regional Analysis of the Oncology Biosimilars Market:

⇥ North America: Leads the market due to advanced infrastructure, strong R&D investments, and early adoption of new technologies.

⇥ Europe: Shows steady growth supported by strict regulations and increasing focus on sustainability initiatives.

⇥ Asia-Pacific: Fastest-growing region driven by rapid industrialization, urbanization, and rising consumer demand in emerging economies.

⇥ Latin America: Experiences moderate growth with expansion in industrial and commercial sectors.

⇥ Middle East & Africa: Gradual market growth supported by increasing investments and improving economic conditions.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=oncology-biosimilars-market

Key Benefits of the Report:

⏩ Comprehensive Market Insights: Gain a deep understanding of market size, trends, and structure.

⏩ Accurate Forecasting: Access reliable future projections to support long-term planning.

⏩ Competitive Analysis: Identify key players, strategies, and positioning in the market.

⏩ Data-Driven Decisions: Make informed business choices backed by verified data.

⏩ Opportunity Identification: Discover emerging trends and untapped growth areas.

⏩ Risk Mitigation: Reduce uncertainties with thorough market evaluation.

⏩ Customer Insights: Understand consumer behavior, preferences, and buying patterns.

⏩ Strategic Planning Support: Align business strategies with market realities.

⏩ Time & Cost Efficiency: Save resources by leveraging ready-to-use research.

⏩ Customization & Expert Validation: Benefit from tailored insights and industry expert analysis.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Oncology Biosimilars Market in 2025?
◆ What is the projected growth rate of the Oncology Biosimilars Market through 2033?
◆ Who are the key players in the Oncology Biosimilars Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Fabian
Email: fabian@datamintelligence.com
Phone USA: +1 877-441-4866
Phone UK: +44 161-870-5507
Website:https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.